Tandem Diabetes CareTNDM
TNDM
3
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,442% more call options, than puts
Call options by funds: $114M | Put options by funds: $7.37M
54% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 89
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
2.06% less ownership
Funds ownership: 111.86% [Q3] → 109.8% (-2.06%) [Q4]
4% less funds holding
Funds holding: 328 [Q3] → 314 (-14) [Q4]
14% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 49
16% less capital invested
Capital invested by funds: $3.11B [Q3] → $2.6B (-$506M) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
25%
upside
Avg. target
$37
111%
upside
High target
$63
259%
upside
8 analyst ratings
3 positive
38%
5 neutral
63%
0 negative
0%
Morgan Stanley Patrick Wood 50% 1-year accuracy 6 / 12 met price target | 25%upside $22 | Equal-Weight Downgraded | 5 Mar 2025 |
Citigroup Joanne Wuensch 38% 1-year accuracy 3 / 8 met price target | 37%upside $24 | Neutral Downgraded | 4 Mar 2025 |
Goldman Sachs David Roman 60% 1-year accuracy 3 / 5 met price target | 37%upside $24 | Neutral Maintained | 3 Mar 2025 |
Wells Fargo Larry Biegelsen 50% 1-year accuracy 2 / 4 met price target | 25%upside $22 | Equal-Weight Downgraded | 3 Mar 2025 |
Barclays Matt Miksic 54% 1-year accuracy 22 / 41 met price target | 202%upside $53 | Overweight Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 4 articles about TNDM published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.
Neutral
Business Wire
2 weeks ago
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem Diabetes Care, Inc. announced NEJM publication of positive results from Control-IQ+ AID technology pivotal trial in type 2 diabetes.
Neutral
Business Wire
2 weeks ago
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company's advanced hybrid closed-loop algorithm. Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes. Pumps pre-loaded with.
Positive
Zacks Investment Research
3 weeks ago
Reasons to Hold TNDM Stock in Your Portfolio for Now
A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.
Negative
Seeking Alpha
1 month ago
Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a beat on revenues of $940m, and on EPS, with a return to positive cash flow. Guidance for 2025 is for revenues of ~$1bn — the growth rate does not seem to have impressed Wall Street, and Q4 underperformance issues also played a part.
Negative
Investors Business Daily
1 month ago
Tandem Diabetes Crashes 32% As Light Outlook Rattles Pump-Maker's Shares
Tandem Diabetes shares crashed Thursday after the insulin pump-maker issued light sales guidance for 2025. The post Tandem Diabetes Crashes 32% As Light Outlook Rattles Pump-Maker's Shares appeared first on Investor's Business Daily.
Neutral
Zacks Investment Research
1 month ago
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.
Neutral
Seeking Alpha
1 month ago
Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer John Sheridan - President & Chief Executive Officer Mark Novara - Executive Vice President & Chief Commercial Officer Leigh Vosseller - Executive Vice President & Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matt Miksic - Barclays Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Shagun Singh - RBC Mike Kratky - Leerink Partners Danielle Antalffy - UBS Jayson Bedford - Raymond James William Plovanic - Canaccord Genuity Mike Polark - Wolfe Research Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Jeff Johnson - Baird Travis Steed - Bank of America Operator Good day and welcome to the Tandem Diabetes Fourth Quarter and Year-End 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Neutral
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Negative
Zacks Investment Research
1 month ago
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago.
Charts implemented using Lightweight Charts™